SORT BY

FILTER BY

fastest growing stats

Fastest Growing Companies

Courtesy of Gilead Sciences

17

Gilead Sciences

GILD

Revenues from new (and safer) HIV meds, including Descovy, Genvoya, and Odefsey, are soothing a drop-off in this biopharma company’s hepatitis C drug sales.

Location

Foster City, Calif.

Industry

Pharmaceuticals

Sector

Health Care

Current Streak

2

Years on List

7

CEO

John Milligan

Gilead Sciences is also featured in these fortune lists
Revenue and net income for the four quarters ended on or before April 30, 2016.Total return for the period ended June 30, 2016.
Revenue, Net Income
$ millions
Revenue Past Four Quarters ($M)$32,839
Net Income Past Four Quarters ($M)$17,341
Growth Rates and Ranks
Revenue 3 Yr Growth Rank9
EPS 3 Yr Annual Growth Rate112%
EPS 3 Yr Growth Rank13
Total Return 3 Yr Annual Rate19%
Total Return 3 Yr Rank66
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Gilead Sciences

What Bill and Hillary Clinton's Controversial Foundation Actually Does

The charity has become a political headache for Hillary Clinton.

Read More →
Why the Fight Against AIDS Still Matters, in One Chart

And why the world needs even more affordable drugs.

Read More →
Pfizer 'In Advanced Talks' to Acquire Medivation for About $14 Billion

Pfizer has agreed to pay a little more than $80 per share for Medivation, a source said.

Read More →
New Poll Shows Millennials Prefer Companies That Give to Charity

Brand reputation isn't necessarily tied to cash giving, however.

Read More →